Understanding TGF-Beta's Role in Tumor Growth and Targeting to the Right Tumor

Rachel Salazar, DHSc, is the SVP, R&D Strategy & Operations at Bicara Therapeutics. A passionate and adaptive organizational leader, Dr Salazar brings more than two decades of experience as a strategic drug development executive in both early and late-stage clinical development. Skilled in strategy development, portfolio management and prioritization, over the past 15 years, Dr Salazar has driven various clinical-stage assets in the oncology and immuno-oncology space to advance therapeutically meaningful and differentiated assets to patients.Prior to joining Bicara, Dr Salazar has held various leadership roles with increasing responsibility in both R&D and Portfolio Management at Pfizer, Takeda Oncology and EMD Serono.Dr Salazar holds both a Bachelor and Master of Science in Biomedical Engineering from Washington University in St. Louis and Tufts University and earned her DHSc from Eastern Virginia Medical School.